METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING A CARTILAGE DAMAGE USING SOX9 GENE
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Dec 12, 2024
app pub date -
Jun 7, 2024
filing date -
Jun 7, 2024
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention is related to a method and pharmaceutical composition for treating a cartilage damage in a subject (including a human or an animal), particularly osteoarthritis (OA), using extracellular vesicles (EVs) with SOX9 gene, called as “EV-SOX9”. The EV-SOX9 is obtained by encapsulating the SOX9 mRNA or the mRNA of its upstream and downstream gene in EVs, naïve EVs with high expression level of SOX9 mRNA or its upstream and downstream gene from different cell sources, or MSC-derived EV-SOX9, which is obtained by transferring the SOX9 gene or its upstream and downstream gene into a multipotent cell and collecting EVs.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully